Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands - Third MMR vaccine dose in young adults (acronym: MMR-3)

RIVM0 个研究点目标入组 147 人开始时间: 2016年5月23日最近更新: 2024年2月19日

适应症

试验速览

暂无简介。

•Healthy young adult 18-25 years of age.
•Previously been immunized with two doses of the MMR vaccine according to the Dutch NIP (MMR-1 at ~14 months and MMR-2 at ~9 years).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 150
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Medical conditions that will severely affect immunological responses to vaccinations, such as, but not limited to, cancer or an immune disorder.
•Vaccination should be postponed during any illness with fever >38.5°C until the fever has disappeared.
•Vaccination with any vaccine during the first two weeks before and four weeks after MMR-3.
•An additional MMR vaccination during the study.
•Coagulation disorder and/or anticoagulant medication.
•Be or have been under immunosuppressive medical treatment, like cytostatics, high-dose corticosteroids, immune globulins, blood or plasma transfusions that might interfere with the results of the study (within the previous 3 months).
•Have or previously had clinical symptoms of mumps virus infection.
•Have or previously had cases of mumps disease within your Household.
•Had experienced a previous severe adverse reaction to any vaccine.
•Being pregnant; Furthermore, pregnancy should be avoided for 1 month following vaccination.
•Breast-feeding women.

发起方

RIVM